ESG

For the 8th straight year, Equashield dominates the CSTD market. We explore the tech, trust, and automation driving its success in protecting workers.

With backing from Shaquille O'Neal and a solid business plan, the UPSHOT League tips off May 15, aiming to reshape the landscape of women's pro basketball.

Dr. Amanda Wilson's appointment to a powerful D.C. council puts her tech-driven addiction treatment model in the national policy spotlight.

How one company turned its internal training program into a strategic powerhouse, earning a top award and creating a blueprint for the future of work.

At a top Paris expo, GUYU's biotech arm BioQ unveiled cellular anti-aging ingredients, signaling a new era of Chinese innovation in the beauty supply chain.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

A new fund, NICO, challenges ESG norms by investing in tobacco giants, aiming to force a shift to safer products. Can engagement succeed where exclusion has failed?

A three-month FDA delay for a new LEQEMBI injection highlights the high-stakes race for a convenient Alzheimer's therapy and its complex safety hurdles.

A KIST-led delegation of Korean quantum startups partners with IBM, signaling a major push to commercialize deep tech on the global stage.

The Federation of Thai Industries' support for IME 2026 creates a vital platform for China-Thailand tech exchange, accelerating the region's digital shift.

A new partnership aims to reshape Australia's booming solar storage sector, bringing advanced all-in-one solutions to homes and installers nationwide.

Avnet's new integration facility in Singapore is more than a building; it's a strategic move in the global shift to diversify tech supply chains beyond China.

With 323 million seniors and a market set to hit ¥30 trillion, China's government is courting global innovators in elderly care. AID 2026 is the gateway.

On Red Dress Day, Métis leaders passed a sacred trust to PM Carney, demanding an end to funding gaps and real action on the stalled MMIWG2S+ crisis.

Facing financial pressures, the biotech divests a key cancer program, repays debt, and now explores all options to maximize value for its remaining pipeline.

The environmental services firm posted sequential growth and cut costs, signaling a strategic pivot despite a year-over-year revenue dip.

Aptar Pharma and the FDA lead a critical mission to reinvent respiratory medicine, ensuring patient safety while tackling the climate impact of inhalers.

The chipmaker topped Q1 estimates and eyes a strong Q2, fueled by EV and AI markets, even as restructuring charges weigh on its bottom line.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

With its stock at an all-time high, Ross Stores' upcoming earnings will be a critical test for the off-price sector's resilience and consumer spending.